These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 23140240)

  • 1. Hepatic and intestinal drug transporters: prediction of pharmacokinetic effects caused by drug-drug interactions and genetic polymorphisms.
    Yoshida K; Maeda K; Sugiyama Y
    Annu Rev Pharmacol Toxicol; 2013; 53():581-612. PubMed ID: 23140240
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dealing with the complex drug-drug interactions: towards mechanistic models.
    Varma MV; Pang KS; Isoherranen N; Zhao P
    Biopharm Drug Dispos; 2015 Mar; 36(2):71-92. PubMed ID: 25545151
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Transporter biology in drug approval: regulatory aspects.
    Maeda K; Sugiyama Y
    Mol Aspects Med; 2013; 34(2-3):711-8. PubMed ID: 23506904
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of Hepatic Drug Transporters in Drug Development.
    Liu H; Sahi J
    J Clin Pharmacol; 2016 Jul; 56 Suppl 7():S11-22. PubMed ID: 27385168
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro and in vivo approaches to characterize transporter-mediated disposition in drug discovery.
    Feng B; Varma MV; Costales C; Zhang H; Tremaine L
    Expert Opin Drug Discov; 2014 Aug; 9(8):873-90. PubMed ID: 24857286
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The use of hepatocytes to investigate drug uptake transporters.
    Maeda K; Sugiyama Y
    Methods Mol Biol; 2010; 640():327-53. PubMed ID: 20645061
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prediction of pharmacokinetics and drug-drug interactions when hepatic transporters are involved.
    Li R; Barton HA; Varma MV
    Clin Pharmacokinet; 2014 Aug; 53(8):659-78. PubMed ID: 25056496
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetic modeling of the hepatobiliary transport mediated by cooperation of uptake and efflux transporters.
    Kusuhara H; Sugiyama Y
    Drug Metab Rev; 2010 Aug; 42(3):539-50. PubMed ID: 20175646
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of drug transporter pharmacogenomics on pharmacokinetic and pharmacodynamic variability - considerations for drug development.
    Lai Y; Varma M; Feng B; Stephens JC; Kimoto E; El-Kattan A; Ichikawa K; Kikkawa H; Ono C; Suzuki A; Suzuki M; Yamamoto Y; Tremaine L
    Expert Opin Drug Metab Toxicol; 2012 Jun; 8(6):723-43. PubMed ID: 22509796
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of transporters in drug interactions.
    Han HK
    Arch Pharm Res; 2011 Nov; 34(11):1865-77. PubMed ID: 22139686
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of interspecies difference in hepatobiliary transporters to improve extrapolation of human biliary secretion.
    Lai Y
    Expert Opin Drug Metab Toxicol; 2009 Oct; 5(10):1175-87. PubMed ID: 19611403
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intestinal transporters for endogenic and pharmaceutical organic anions: the challenges of deriving in-vitro kinetic parameters for the prediction of clinically relevant drug-drug interactions.
    Grandvuinet AS; Vestergaard HT; Rapin N; Steffansen B
    J Pharm Pharmacol; 2012 Nov; 64(11):1523-48. PubMed ID: 23058041
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predicting human hepatic clearance from in vitro drug metabolism and transport data: a scientific and pharmaceutical perspective for assessing drug-drug interactions.
    Camenisch G; Umehara K
    Biopharm Drug Dispos; 2012 May; 33(4):179-94. PubMed ID: 22407504
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recent progresses in the experimental methods and evaluation strategies of transporter functions for the prediction of the pharmacokinetics in humans.
    Kitamura S; Maeda K; Sugiyama Y
    Naunyn Schmiedebergs Arch Pharmacol; 2008 Jun; 377(4-6):617-28. PubMed ID: 18536908
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Why we need proper PBPK models to examine intestine and liver oral drug absorption.
    Chow EC; Pang KS
    Curr Drug Metab; 2013 Jan; 14(1):57-79. PubMed ID: 22935069
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Primary hepatocyte cultures as prominent in vitro tools to study hepatic drug transporters.
    Ramboer E; Vanhaecke T; Rogiers V; Vinken M
    Drug Metab Rev; 2013 May; 45(2):196-217. PubMed ID: 23368091
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interplay of pharmacogenetic variations in ABCB1 transporters and cytochrome P450 enzymes.
    Yoo HD; Lee YB
    Arch Pharm Res; 2011 Nov; 34(11):1817-28. PubMed ID: 22139683
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The evolution of the OATP hepatic uptake transport protein family in DMPK sciences: from obscure liver transporters to key determinants of hepatobiliary clearance.
    Fenner KS; Jones HM; Ullah M; Kempshall S; Dickins M; Lai Y; Morgan P; Barton HA
    Xenobiotica; 2012 Jan; 42(1):28-45. PubMed ID: 22077101
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Physiologically based pharmacokinetic modeling of intestinal first-pass metabolism of CYP3A substrates with high intestinal extraction.
    Gertz M; Houston JB; Galetin A
    Drug Metab Dispos; 2011 Sep; 39(9):1633-42. PubMed ID: 21632965
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prediction of pharmacokinetics and drug-drug interactions from in vitro metabolism data.
    Shou M
    Curr Opin Drug Discov Devel; 2005 Jan; 8(1):66-77. PubMed ID: 15679174
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.